Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed)
Posted by National Institutes of Health
Opportunity snapshot. This Grants.gov announcement — Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed) — is cataloged under number RFA-CA-23-037 and tied to CFDA assistance listing 93.395, posted by National Institutes of Health. Grants.gov currently shows the opportunity as closed, first posted on July 17, 2023. The funding category is Discretionary, delivered as a cooperative agreement.
Award economics. The award range on file is Up to $1,500,000. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on November 15, 2023. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully — federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed — it helps clarify scope and scoring priorities.
Award Range
Up to $1,500,000
Close Date
November 15, 2023
Posted
July 17, 2023
Instrument
Cooperative Agreement
Description
NCI is forming the Targeting Fusion Oncoproteins in Childhood Cancers (TFCC) Network to advance our understanding of the mechanisms of action of fusion oncoproteins in pediatric cancers and to apply novel chemical strategies for developing targeted therapeutic approaches. This RFA will use the UM1 mechanism to fund Next Generation Chemistry Centers (NGC) for Fusion Oncoproteins that have independent research projects using innovative chemical biology technologies and chemoproteomic approaches to target fusion-driven cancers. The goal of these discovery efforts will be to identify and develop small molecules that effectively disrupt fusion oncoproteins through mechanisms including, but not limited to, inhibiting activities of individual fusion oncoproteins, blocking critical fusion protein interactions, interacting with coding and/or noncoding RNAs required for fusion protein oncogenesis, and selectively inducing fusion protein degradation or degradation of proteins representing critical fusion oncoprotein dependencies. Compounds envisaged to be derived from these efforts may be either at the level of chemical probes and tools to delineate underlying biology, advanced leads to support further optimization to a candidate, or potential drug candidates themselves. In addition to the research proposed in their applications, each NGC Center will be expected to participate in collaborative projects with the U01s and potentially other members of the fusion oncoprotein community. Funding priority will be given to applications that focus on fusion oncoproteins found in tumors that have high risk of treatment failure and for which there has been little progress in identifying targeted agents. Applications focused on high-risk pediatric solid tumors and brain cancers are particularly encouraged. UM1 recipients will meet regularly with U01 grantees funded through the Mechanisms of Fusion-Driven Oncogenesis in Childhood Cancers FOA.
Eligibility
00;01;02;04;05;06;07;08;11;12;13;20;22;23;25
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Cancer Treatment Research
National Institutes of Health
Agency Contact
NIH Grants Information<br/>grantsinfo@nih.gov
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from National Institutes of Health
Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
Research Grants in Clinical Informatics (R01 Clinical Trial Optional)
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology — how this data is sourced, computed, and verified.
Related
| Publisher | Kiznis Studio |
| Sources | Public official public datasets |